Amazon Bio Discovery, announced last week, is designed to offer scientists direct access to a wide range of specialized AI models known on biological foundation models (bioFMs) that are trained using large biological datasets.
“These models generate and evaluate potential drug molecules, known as candidates, helping scientists accelerate antibody therapies during the early stages of drug discovery,” the announcement said. “But access alone is not enough.”
Amazon Bio Discovery allows scientists to converse naturally in their preferred terminology with an AI agent to choose the appropriate models for their research goals, optimize inputs and gauge candidates for experimentation, the announcement said.
In addition, scientists also train models on their prior experimental data for more accurate predictions, and send candidates to physical labs for synthesis and testing, “with results routing back to the application for rapid iteration, creating a lab-in-the-loop experimentation cycle,” the announcement added.
“AI agents make powerful scientific capabilities accessible to all drug researchers, not just those with computational expertise,” Rajiv Chopra, vice president of AWS healthcare AI and life sciences, said in the announcement.
Advertisement: Scroll to Continue
“These AI systems can help scientists design drug molecules, coordinate testing, learn from results, and get smarter with each experiment. This combination of cutting-edge AI and the robust, secure infrastructure AWS has built for regulated industries allows scientists to accelerate antibody discovery in ways that weren’t possible before.”
The announcement comes as pharmaceutical companies are reshaping their operating models around AI to offset the cost of drug development, as PYMNTS wrote earlier this year.
“By embedding machine learning into trial execution and compliance infrastructure, drugmakers are targeting the most costly and failure-prone bottlenecks in how therapies are tested, reviewed and ultimately brought to market,” that report said.
Big Tech and hardware players are entering these workflows, blurring the boundaries between IT and life sciences. For instance, Nvidia and Eli Lilly announced a co-innovation lab to drive drug discovery.
Meanwhile, Google’s research division is using Gemma AI models for cancer therapy discovery, showing how large-language and generative models can analyze biological pathways and suggest novel therapeutic hypotheses.
“Taken together, these developments point to a broader reality: AI is no longer a niche computational aid in early R&D,” that report said. “It is becoming an end-to-end operational ecosystem that supports patient selection, safety monitoring, documentation generation, trial logistics and regulatory engagement.”
For all PYMNTS AI coverage, subscribe to the daily AI Newsletter.
